Albain KS, Swann RS, Rusch VW, et al: Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: A phase III randomised controlled trial. Lancet 374:379–386, 2009.
Annema JT, van Meerbeeck JP, Rintoul RC, et al: Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: A randomized trial. JAMA 304:2245–2252, 2010.
Arriagada R, Dunant A, Pignon JP, et al: Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin(Drug information on cisplatin)-based chemotherapy in resected lung cancer. J Clin Oncol 28:35–42, 2010.
Azzoli CG, Temin S, Aliff T, et al: 2011 Focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 29:3825–3831, 2011.
Bach PB, Jett JR, Pastorino U, et al: Computed tomography screening and lung cancer outcomes. JAMA 297:953–961, 2007.
Bergethon K, Shaw AT, Ou SH, et al: ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30:863–870, 2012.
Blumenschein GR Jr, Paulus R, Curran WJ, et al: Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol 29:2312–2318, 2011.
Brenner DJ, Hall EJ: Computed tomography—An increasing source of radiation exposure. N Engl J Med 357:2277–2284, 2007.
Cappuzzo F, Ciuleanu T, Stelmakh L, et al: SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following non-progression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J Clin Oncol 27(15S): abstract 8001, 2009.
Chang JY, Komaki R, Lu C, et al: Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer 2011 Mar 22. [Epub ahead of print].
Chen Y, Moon J, Pandya KJ, et al: Pilot study (SWOG S0429) of weekly cetuximab and chest radiotherapy (RT) for poor-risk stage III non-small cell lung cancer (NSCLC). J Clin Oncol 29(suppl): abstract 7040, 2011.
Ciuleanu T, Brodowicz T, Zielinski C, et al: Maintenance pemetrexed(Drug information on pemetrexed) plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374:1432–1440, 2009.
Crinò L, Kim D, Riely JG, et al: Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol 29[suppl]: abstract 7514, 2011.
Curran WJ Jr, Paulus R, Langer CJ, et al: Sequential vs. concurrent chemoradiation for stage III non-small-cell lung cancer: Randomized phase III trial RTOG 9410. J Natl Cancer Inst 103:1452–1460, 2011.
Douillard JY, Tribodet H, Aubert D, et al: Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: Subgroup analysis of the Lung Adjuvant Cisplatin Evaluation. J Thorac Oncol 5:220–228, 2010.
Fidias PM, Dakhil SR, Lyss AP, et al: Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin(Drug information on carboplatin) in advanced non-small-cell lung cancer. J Clin Oncol 27:591–598, 2009.
Gore EM, Bae K, Wong SJ, et al: Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: Primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol 29:272–278, 2011.
Govindan R, Bogart J, Wang X, et al: Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: CALGB 30407. J Clin Oncol 27(15S): abstract 7505, 2009.
Grønberg BH, Bremnes RM, Fløtten O, et al: Phase III study by the Norwegian lung cancer study group: Pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 27:3217–3224, 2009.
Grunnet M, Sorensen JB: Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer 76:138–143, 2012.
Hanna N. Neubauer M, Yiannoutso SC, et al: Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: The Hoosier Oncology Group and US Oncology. J Clin Oncol 26:5755–5760, 2008.
Hanna N, Shepherd FA, Fossella FV, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non–small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589–1597, 2004.
Hughes JR, Stead LF, Lancaster T: Antidepressants for smoking cessation. Cochrane Database Syst Rev. Jan 24;(1):CD000031, 2007.
International Early Lung Cancer Action Program Investigators; Henschke CI, Yankelevitz DF, Libby DM, et al: Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 355:1763–1771, 2006.
Karp DD, Paz-Ares LG, Novello S: High activity of the anti-IGF-IR antibody CP-751,871 in combination with paclitaxel(Drug information on paclitaxel) and carboplatin in squamous NSCLC. J Clin Oncol 26(15 Suppl):8015, 2008.
Karp DD, Lee SJ, Shaw Wright GL, et al: A phase III, intergroup, randomized, double-blind, chemoprevention trial of selenium(Drug information on selenium) (SE) supplementation in resected stage I non-small cell lung cancer (NSCLC). J Clin Oncol 28(18S): abstract 7004, 2010.
Komaki R, Sejpal SV, Wei X, et al: Significant reduction of bone marrow toxicity for patients with locally advanced NSCLC treated with concurrent chemotherapy and proton beam therapy compared to intensity modulated radiation therapy. Radiother Oncol 90:S61, 2009.
Lilenbaum RC, Herndon JE 2nd, List MA, et al: Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: The Cancer and Leukemia Group B (study 9730). J Clin Oncol 23:190–196, 2005.
Miller VA, O'Connor P, Soh C, et al: A randomized, double-blinded, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab therapy with or without erlotinib after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer. J Clin Oncol 27(18S): abstract LBA8002, 2009.
Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957, 2009.
Movsas B, Moughan J, Sarna L, et al: Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. J Clin Oncol 27:5816–5822, 2009.
Paz-Ares LG, de Marinis F, Dediu M, et al: Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 13:247–555, 2012.
Paz-Ares LG, de Marinis F, Dediu M, et al: PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). J Clin Oncol. 30(18S): abstract LBA7507, 2012.
Peng G, Tinner RG, Wang Y, et al: Comparison of patient outcomes stratified by histology among pemetrexed (P)-treated patients with stage IIIB/IV non-small cell lung cancer (NSCLC) in two phase II trials. J Clin Oncol 26(15S): abstract 8096, 2008.
Pirker R, Szczesna A, von Pawel J, et al: FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 26(15S): abstract 3, 2008.
Pisters K, Vallieres E, Bunn PA, et al: S9900: Surgery alone or surgery plus induction (ind) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Follow-up on a phase III trial. J Clin Oncol 25(18S): abstract 7520, 2007.
Ramlau R, Zatloukal P, Jassem J, et al: Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I. J Clin Oncol 26:1886–1892, 2008.
Riely GJ, Brahmer JR, Planchard D, et al: A randomized discontinuation phase II trial of ridaforolimus in non-small-cell lung cancer (NSCLC) patients with KRAS mutations. J Clin Oncol 30(15S): abstract 7531, 2012.
Rodrigues G, Videtic G, Sur R, et al: Palliative thoracic radiotherapy in lung cancer: An American Society for Radiation Oncology evidence-based clinical practice guideline. Pract Radiat Oncol 1:60–71, 2011.
Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550, 2006.
Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543–3551, 2008.
Senan S, Verstegen NE, Haasbeek CJ, et al: Outcomes of stereotactic body radiotherapy in patients with clinical stage I non-small cell lung cancer who are fit to undergo surgery. J Clin Oncol 29(suppl): abstract 7051, 2011.
Shaw AT, Yeap BY, Mino-Kenudson M, et al: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27:4247–4253, 2009.
Shaw AT, Yeap BY, Solomon BJ, et al: Impact of crizotinib on survival in patients with advanced ALK-positive NSCLC compared with historical controls. J Clin Oncol 29(suppl): abstract CRA7507, 2011.
Siegel R, Naishadham D, Jemal A, et al: Cancer statistics, 2012. CA Cancer J Clin 62:10–29, 2012.
Simon G: Personalized chemotherapy may favorably alter intrinsic disease biology to produce a higher proportion of long term survivors in patients with advanced NSCLC (abstract D7.6). Presented at the Annual Meeting of the International Association for the Study of Lung Cancer; San Francisco; July 31-August 4, 2009.
Spigel DR, Ervin TJ, Ramlau R, et al: Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol 29(suppl): abstract CRA7505, 2011.
Sun A, Bae K, Gore EM, et al: Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: Neurocognitive and quality-of-life analysis. J Clin Oncol 29:279-286, 2010.
Timmerman R, McGarry R, Yiannoutsos C, et al: Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early stage lung cancer. J Cllin Oncol 24:4833–4839, 2006.
Timmerman R, Paulus R, Galvin J, et al: Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303:1070-1076, 2010.
Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 28:2443–2454, 2012.
Travis WD, Brambilla E, Noguchi M, et al: International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6:244–285, 2011.
Vincent MD, Butts C, Seymour L, et al: Updated survival analysis of JBR.10: A randomized phase III trial of vinorelbine/cisplatin versus observation in completely resected stage IB and II non-small cell lung cancer (NSCLC). J Clin Oncol 27(15S): abstract 7501, 2009.